Transcription start site analysis of Streptococcus agalactiae strain BM110

Streptococcus agalactiae, also known as Group B streptococcus, emerged in the 1960s as a leading cause of septicemia and meningitis in neonates. It is also an increasing cause of infections in adults with underlying diseases. To characterize transcription start sites (TSS) in the hypervirulent ST17 lineage (strain BM110) we used a differential RNA-seq strategy, based on selective Tobacco Acid Pyrophosphatase (TAP) treatment and adapter ligation, which differentiates primary transcripts and processed RNAs We analyzed three dRNA seq experiments (TAP-treated versus TAP-untreated RNA) on the following RNA samples: 1) a pool of BM110 RNA prepared under mid-exponential (O.D600= 0.4) and early stationary phase (O.D600= 1.2) in a rich growth medium (TH) and under stationary phase (O.D600= 0.35) in a poor culture medium; 2) RNA prepared from a transconjugate of BM110 (after TnGBS1 transfer; TnGBS under non-integrated form) cultivated in a rich medium (TH) to late-exponential phase (O.D600= 0.8) in the presence of tetracycline 10mg/l; RNA from BM110 cultivated in a rich medium (TH) to late-exponential phase (O.D600= 0.8) in the presence of tetracycline 10mg/l.